Advanced Enzyme Technologies Ltd
NSE: ADVENZYMES BSE: 540025
₹294.90
(1.10%)
Thu, 19 Mar 2026, 00:27 am
Market Cap32.71B
PE Ratio21.69
Dividend1.78
Consumer Non-Durables
Food: Specialty/Candy
24.5KAdvanced Enzyme Technologies Analysis
dividend
- Advanced Enzyme Technologies is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Advanced Enzyme Technologies's dividends as it is not paying a notable one for India.
- Advanced Enzyme Technologies is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Advanced Enzyme Technologies's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Advanced Enzyme Technologies's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Advanced Enzyme Technologies's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Advanced Enzyme Technologies's earnings are expected to exceed the low risk growth rate next year.
- Performance (ROE) is expected to be above the current IN Chemicals industry average.
- An improvement in Advanced Enzyme Technologies's performance (ROE) is expected over the next 3 years.
- Advanced Enzyme Technologies's revenue growth is expected to exceed the India market average.
- Advanced Enzyme Technologies's earnings are expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).
- Advanced Enzyme Technologies's earnings growth is positive but not above the India market average.
- Advanced Enzyme Technologies's net income is expected to increase but not above the 50% threshold in 2 years time.
- Advanced Enzyme Technologies is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Advanced Enzyme Technologies's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Advanced Enzyme Technologies's revenue is expected to grow by 8.5% yearly, however this is not considered high growth (20% yearly).
health
- Advanced Enzyme Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Advanced Enzyme Technologies is profitable, therefore cash runway is not a concern.
- Advanced Enzyme Technologies is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (845.8%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 22.8x debt.
- Advanced Enzyme Technologies's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (70% vs 1.9% today).
- Interest payments on debt are well covered by earnings (EBIT is 60x coverage).
- Advanced Enzyme Technologies's level of debt (1.9%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- More shares have been bought than sold by Advanced Enzyme Technologies individual insiders in the past 3 months.
- The tenure for the Advanced Enzyme Technologies management team is about average.
- The average tenure for the Advanced Enzyme Technologies board of directors is less than 3 years, this suggests a new board.
misc
- Advanced Enzyme Technologies is covered by less than 3 analysts.
- Advanced Enzyme Technologies has significant price volatility in the past 3 months.
past
- Advanced Enzyme Technologies's 1-year earnings growth exceeds its 5-year average (16.4% vs 13.4%)
- Advanced Enzyme Technologies's year on year earnings growth rate has been positive over the past 5 years.
- Advanced Enzyme Technologies used its assets more efficiently than the IN Chemicals industry average last year based on Return on Assets.
- Advanced Enzyme Technologies's earnings growth has exceeded the IN Chemicals industry average in the past year (16.4% vs 9.1%).
- Advanced Enzyme Technologies's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Advanced Enzyme Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- 540025 outperformed the Market in India which returned -14.5% over the past year.
- Advanced Enzyme Technologies's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Advanced Enzyme Technologies's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Advanced Enzyme Technologies is overvalued based on assets compared to the IN Chemicals industry average.
- Advanced Enzyme Technologies is poor value based on expected growth next year.
- Advanced Enzyme Technologies is overvalued based on earnings compared to the IN Chemicals industry average.
- Advanced Enzyme Technologies is overvalued based on earnings compared to the India market.
- 540025 underperformed the Chemicals industry which returned 2.2% over the past year.
- BSE:540025 is up 5.9% underperforming the Chemicals industry which returned 6.9% over the past month.
- BSE:540025 is up 5.9% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800